- The trial rationale and protocol were presented at the
"Targeted Anticancer Therapies" congress in Paris
- Phase I/II of IPH2201 as a single agent will begin in the
next few months
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 -
IPH), the innate immunity company developing first-in-class
therapeutic antibodies for cancer and inflammatory diseases, today
announced that investigators from NCIC Clinical Trials Group ("NCIC
CTG") presented the rationale and protocol of the Phase I/II trial
of IPH2201, a first-in-class NKG2A checkpoint inhibitor, as a
single agent in platinum resistant or sensitive patients with high
grade ovarian cancer at the 13th International Congress on Targeted
Anticancer Therapies ("TAT").
NCIC CTG is sponsoring the study (known as IND.221) which will
be conducted in Canada and enroll patients with ovarian
cancer. In the first part of the study patients will receive
IPH2201 at one of three dose levels. Thereafter 20 additional
patients will be enrolled, in two groups, including patients whose
ovarian cancer is felt to be either platinum sensitive or
resistant.
Pierre Dodion, Chief Medical Officer of Innate Pharma, said: "We
are very pleased to work with NCIC CTG, a cooperative group of
international reputation with extensive experience in treating
ovarian cancer. This second trial will begin in the next few
months, in line with our plan to activate several Phase II studies
with IPH2201 in 2015".
Lesley Seymour, Director of the Investigational New Drug Program
at NCIC CTG said: "NCIC CTG is conducting and planning a number of
trials testing agents in the emerging field of immune-based
treatments for patients with cancer. Ovarian cancer is an area of
unmet need and there is a good scientific rationale for testing
immune-based treatments in this disease. NKG2A is a novel target in
this exciting area. IPH2201 was shown to have a good safety profile
in a Phase I safety trial in patients with rheumatoid arthritis.
NCIC CTG is excited to test this first-in-class checkpoint
inhibitor in patients with recurrent ovarian cancer".
The rationale of the trial is based on the frequent
(approximately 70 to 80% of the patients) upregulation of HLA-E,
the ligand of NKG2A, in ovarian cancer (Gooden, OncoImmunol, 2012).
HLA-E overexpression is a poor prognostic factor in gynecologic
tumors (Gooden, PNAS, 2011). Furthermore, the presence of
tumor-infiltrating lymphocytes correlates with improved outcome
(Zhang, N Engl J Med, 2003; Sato, PNAS, 2005) especially in those
cancers with high HLA-E expression (Gooden, PNAS, 2011). Binding of
IPH2201 to NGK2A blocks the HLA-E driven inhibition of NK and CD8+
cells. The resulting stimulation of both the innate and acquired
immunity could lead to clinical and pharmacological antitumor
activity. In a Phase I dose-escalation safety trial, IPH2201
appeared to have a safe and well-tolerated profile. Phase I safety,
PK and PD data of IPH2201 were also presented during the
congress.
The presentation is available on Innate Pharma's website,
section pipeline/IPH2201.
About Ovarian Cancer:
Ovarian cancers represents around 4% of all cancers in women
(overall incidence: 12/100,000; incidence in 65-69 years old women:
61/100,000). Ovarian cancer is the leading cause of death in
gynecologic cancers and the fifth most common site of cancer. High
Grade Serous Carcinoma ("HGSC") of the ovary is the most common
subtype of all ovarian cancers representing nearly 60% of all
cases. Given the absence of effective screening strategies, HGSC of
the ovary is typically diagnosed in advanced stages (stages III and
IV). While survival has been prolonged by multimodality treatment
(extensive surgery and multiagent chemotherapy), cure remains
elusive for the majority of patients with stage III and IV disease
with an overall 5-year survival rate of around 30%.
Platinum resistant disease (defined as relapse within 6 months
after platinum chemotherapy) is associated with a poor response to
salvage therapy (response rate < 15%) and a particularly poor
prognosis (median survival 12-18 months). Although the outlook is
better for patients with disease which is considered to be platinum
sensitive, eventually multiagent resistance develops. Overall,
recurrent ovarian cancer remains a significant unmet medical
need.
About IPH2201:
IPH2201 is a first-in-class immune checkpoint inhibitor
targeting NKG2A receptors expressed on tumor infiltrating cytotoxic
NK and CD8 T lymphocytes.
NKG2A is an inhibitory receptor binding HLA-E. By expressing
HLA-E, cancer cells can protect themselves from killing by NKG2A+
immune cells. HLA-E is frequently up-regulated on cancer cells of
many solid tumors or hematological malignancies. IPH2201, a
humanized IgG4, blocks the binding of NKG2A to HLA-E allowing
activation of NK and cytotoxic T cell responses. Hence, IPH2201 may
re-establish a broad anti-tumor response mediated by NK and T
cells. IPH2201 may also enhance the cytotoxic potential of other
therapeutic antibodies.
About NCIC CTG
The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical
trials cooperative group that conducts Phase I-III trials testing
anti-cancer and supportive therapies across Canada and
internationally. It is a national research program of the Canadian
Cancer Society. The NCIC CTG's Central Operations and Statistics
Office is located at Queen's University in Kingston, Ontario,
Canada.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company discovering
and developing first-in-class therapeutic antibodies for the
treatment of cancer and inflammatory diseases.
Its innovative approach has translated into major alliances with
leaders in the biopharmaceutical industry such as Bristol-Myers
Squibb and Novo Nordisk A/S.
The Company has two clinical-stage programs in immuno-oncology,
a new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to
recognize and kill cancer cells. Innate Pharma's science also has
potential in chronic inflammatory diseases.
Listed on Euronext-Paris, Innate Pharma is based in Marseille,
France, and had 99 employees as at December 31, 2014.
Learn more about Innate Pharma at www.innate-pharma.com
Practical Information about Innate Pharma shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. For a
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors ("Facteurs de Risque")
section of the Document de Reference prospectus filed with the AMF,
which is available on the AMF website (http://www.amf-france.org)
or on Innate Pharma's website.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Innate Pharma |
ATCG
Press |
Laure-Hélène Mercier Director, Investor
Relations |
Judith Aziza, Mob.:+33
(0)6 70 07 77 51 Marielle Bricman, Mob.:+33 (0)6 26 94 18 53 |
Tel.: +33 (0)4 30 30 30 87 |
|
investors@innate-pharma.com |
presse@atcg-partners.com |
PR NCIC http://hugin.info/155662/R/1900188/675305.pdf
HUG#1900188
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024